Debulking Surgery for Ovarian Cancer

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Debulking Surgery for Ovarian Cancer trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

RecruitingPhase 2

NCT07229040

A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patient…

To compare cilastatin vs thiosulfatein renal protection in patients undergoing debulking surgery with intraoperative hyperthermic intraperitoneal chemotherapy w…

Spain90 participantsStarted 2025-02-21

Treatment: cilastatine, tiosulfate

RecruitingNot Applicable

NCT06533709

Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data

This project intends to conduct a multicenter retrospective study to evaluate the satisfactory reduction of advanced ovarian cancer using PET-CT images, and exp…

China146 participantsStarted 2024-06-01

Treatment: Radio-score

All recent trials (17 shown)

CompletedNot Applicable

NCT07567573

Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery

This study, organized by the European Society of Gynaecological Oncology (ESGO), evaluates the clinical impact of adherence to ten ESGO-established quality indi…

Belgium11,383 participantsStarted 2023-04-26

Treatment: Preoperative Evaluations, Cytoreductive Surgery

Active — Not RecruitingPhase 3

NCT03772028

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy

United States, Denmark, France538 participantsStarted 2020-01-01

Treatment: cisplatin

Debulking Surgery for Ovarian Cancer

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patient…

Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data

All recent trials (17 shown)

Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Trial phase breakdown

Trial status

Actively recruiting — 2 trials

A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patient…

Satisfactory Debulking Prediction Model for Advanced Ovarian Cancer Based on PET-CT Image Data

All recent trials (17 shown)

Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery

Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Ca…

Study of Nutritional Supplement Shakes in People About to Receive Their Debulking Surgery for Ovarian Cancer

Tolerance of Intraperitoneal (IP) Nivolumab After Extensive Debulking Surgery and Hyperthermic Intraperitoneal Chemother…

Prehabilitation in Ovarian Cancer Patients During Chemiotherapy Before Cytoreductive Surgery.

Study of Upfront Surgery Versus Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer (SUNNY)

Visualisation of Indocyanine Green in Primary and Interval Debulking for Ovarian Cancer

Short-course HIPEC in Advanced Epithelial Ovarian Cancer

Paclitaxel, Bevacizumab And Adjuvant Intraperitoneal Carboplatin in Treating Patients Who Had Initial Debulking Surgery…

Secondary Debulking Surgery +/- Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer

Feasibility of Interval Debulking Surgery by Laparoscopy for Peritoneal Carcinosis in Chemosensitive Patients

A Phase II Combined Modality Protocol of Debulking Surgery With HIPEC Followed by Intraperitoneal Chemotherapy for the T…

Accelerating Gastrointestinal Recovery

A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer